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ABSTRACT
Objective: To analyse the treatment outcome of
patients with ankylosing spondylitis (AS) in the
European AS infliximab cohort (EASIC) study after a total
period of 8 years with specific focus on dosage and the
duration of intervals between infliximab infusions.
Methods: EASIC included patients with AS who had
received infliximab for 2 years as part of the ASSERT
trial. After that period, rheumatologists were free to
change the dose or the intervals of infliximab. Clinical
data were status at baseline, end of ASSERT and for a
total of 8 years of follow-up.
Results: Of the initially 71 patients with AS from
EASIC, 55 patients (77.5%) had completed the 8th year
of anti-tumour necrosis factor (TNF) treatment. Of those,
48 patients (87.3%) still continued on infliximab. The
mean infusion interval increased slightly from 6 to 7.1
±1.5 weeks, while 45.8% patients had increased the
intervals up to a maximum of 12 weeks. The mean
infliximab dose remained stable over time, with a
minimum of 3.1 mg/kg and a maximum of 6.4 mg/kg.
In patients receiving <5 mg/kg infliximab, the mean
infusion interval increased to 7.0±1.2 weeks. In total, the
mean cumulative dose per patient and per year
decreased from 3566.30 to 2973.60 mg.
Conclusions: We could observe that over a follow-up
of 8 years of treatment with infliximab, >85% patients
still remained on the same treatment, without any major
safety events. Furthermore, both the infusion intervals
and also the mean infliximab dose were modestly
reduced in ≥70% of the patients without the loss of
clinical efficiency.
Ankylosing spondylitis (AS), the main subtype
of spondyloarthritides (SpA), is a chronic
inﬂammatory rheumatic disease that affects
about 0.5% of the adult Caucasian popula-
tion and usually starts in early adulthood.1
AS is clinically characterised by inﬂammatory
back pain due to sacroiliac and/or spinal
inﬂammation which may eventually lead to
an increase in new bone formation.
Non-steroidal anti-inﬂammatory drugs are
considered as ﬁrst line pharmacological
therapy for AS. However, international
recommendations advise the use of tumour
necrosis factor (TNF) blockers for patients
with AS who have persistently high disease
activity despite conventional treatment.2
Several trials have shown that treatment
with inﬂiximab is efﬁcacious in patients with
active AS, conﬁrming the ﬁndings of the
pivotal Ankylosing Spondylitis Study for the
Evaluation of Recombinant Inﬂiximab
Therapy (ASSERT) trial with 279 patients.3
MRI revealed a signiﬁcant decrease in spinal
inﬂammation in this study.4 Whether TNF
blockers slow or inhibit structural damage in
AS is still a matter of debate.5
Long-term data on the clinical efﬁciency
and safety of anti-TNF therapy in AS are still
Key messages
What is already known about this subject?
▸ Anti-TNF treatment is the gold standard in
patients with axial spondyloarthritis. Patients
treated with anti-TNF need to stay on this treat-
ment over many years.
What does this study add?
▸ Doses of infliximab in patients with axial spon-
dyloarthritis may be modified and decreased in
the long-term.
How might this impact on clinical practice?
▸ Physicians may consider adapting the doses of
infliximab in patients who show good and sus-
tained clinical response in the long term.
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scarce.6 7 However, such data are critical for appropriate
economic analyses related to anti-TNF therapy.8
The European AS inﬂiximab cohort (EASIC) was
initiated by a group of European rheumatologists as an
open label investigator-driven international multicentre
trial9 with patients who had received inﬂiximab for
2 years as part of the ASSERT trial.10 In this trial, which
was one of the ﬁrst trials with anti-TNF therapy, the
disease activity of the included patients was relatively
high as compared to later clinical trials with increased
but still showed relatively milder signs and symptoms of
disease activity. All the patients were initially treated with
inﬂiximab at the usual dosage of 5 mg/kg after the
initial saturation phase. After 2 years of continuous treat-
ment (end of ASSERT, extension phase to EASIC), rheu-
matologists were free to change the dose or the intervals
of inﬂiximab. The latest data of all the patients after
7 years of continuous inﬂiximab treatment are now
being published with the focus on treatment efﬁciency
and safety.11
In the current report, we present the results of the
patients completing the EASIC extension after a total
treatment period of 8 years and with speciﬁc focus on
dosage and the duration of intervals between inﬂiximab
infusions.
Of the 71 patients with AS who were initially included
in EASIC, 55 patients completed the eighth year of
anti-TNF treatment (77.5%). Of those, 48 patients still
continued on inﬂiximab (87.3%), while the remaining 7
patients switched to another biological agent for differ-
ent reasons (12.7%). The reasons for dropping out of
EASIC have already been reported elsewhere.10 At base-
line, the mean age of these 55 patients was 50.6
±8.5 years and 40 patients (83.3%) were male.
The mean interval between infusions increased slightly
between year 2 (end of ASSERT) and year 8, from
6.0±1.0 weeks (as per initial study protocol) to
7.1±1.5 weeks, respectively. Overall, 24/48 patients
(50%) still received inﬂiximab in a standardised way
with 6-week intervals between infusions, while 22/48
patients (45.8%) had increased the intervals up to a
maximum of 12 weeks and 2/48 patients (4.2%)
received inﬂiximab every 5 weeks. The mean dose and
the mean weight of the patients remained stable over
time. The mean weight was 82.3±15.1 kg at start of
ASSERT (baseline), 82.2±15.6 kg at the end of ASSERT
(year 2) and 82.5±15.5 kg at the end of EASIC (year 8).
The mean dose of inﬂiximab per infusion and per
patient was 4.7±0.8 mg/kg at baseline, 4.6±0.8 at year 2
and 4.7±0.8 at year 8, with a minimum dose of 3.1 mg/
kg and a maximum dose of 6.4 mg/kg. In more detail,
30 patients (62.5%) were receiving a dose <5 mg/kg, 5
patients (10.4%) remained at 5 mg/kg and 13 patients
(27.1%) had increased their dose to up to 6.4 mg/kg.
Furthermore, there were numerical differences between
the mean dose of inﬂiximab and the dose interval at the
end of the study. In the group of patients receiving a
dose of <5 mg/kg of inﬂiximab, the mean infusion
Figure 1 Course of the mean cumulative dose per patient and year (black line, in mg infliximab) and mean infusion interval
(grey line, in weeks) over the 8 years of treatment with infliximab in European ankylosing spondylitis infliximab cohort (EASIC).
Figure 2 Course of disease related outcomes for efficiency
over the entire study period of 8 years. Data are presented are
mean values for all completers of the present analysis still
being treated with infliximab (n=48, CRP mg/dL). BASDAI,
Bath Ankylosing Spondylitis Disease Activity Index; BASFI,
Bath Ankylosing Spondylitis Functional Index; BASMI, Bath
Ankylosing Spondylitis Metrology Index; CRP, C reactive
protein.
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interval at year 8 was 7.0±1.2 weeks, while in the group
receiving a dose of 5 mg/kg of inﬂiximab it was 7.4
±1.3 weeks and in the group receiving a dose >5 mg/kg
of inﬂiximab was 6.6±1.9 weeks. In total, the mean
cumulative dose per patient and per year decreased
from 3566.30 to 2973.60 mg (ﬁgure 1, Wilcoxon
p<0.001).
Throughout the observation period, the mean Bath
AS Disease Activity Index, Bath AS Functional Index,
and the patient’s global and C reactive protein values
remained low without differences between year 2 and
year 8 of the study, with exception of the Bath AS
Metrology Index, which initially improved but returned
to values similar to those noted at baseline (ﬁgure 2).
This observation made late in the course of the study
can be possibly explained by the natural decrease in
spinal mobility that develops with age—similar to what
has been described also for normal individuals over a
similar time period.12
In this present additional follow-up study there were
no additional safety signals as compared to previous
reports on EASIC.10 13
Taken together, the EASIC cohort is one of the largest
cohorts of patients with AS (or radiographic axial SpA)
receiving treatment with inﬂiximab. These results
conﬁrm the favourable outcome of patients with AS who
received anti-TNF therapy over many years. The persist-
ently decreased values of the clinical variables suggest a
good control of disease activity and function. We could
observe that over a follow-up period of 8 years of treat-
ment with inﬂiximab, including 5 years of treatment in
daily practice and not based on a standardised treatment
protocol, more than 85% of the patients still remained
on inﬂiximab treatment, without experiencing any
major safety events. Furthermore, the infusion intervals
and the mean inﬂiximab dose, were modestly reduced
in ≥70% of the patients without any loss of clinical
efﬁciency.
As far as we are aware, this is a rather unique experi-
ence with the use of a TNF blocker in patients with AS
in a real world setting. Since the data were collected in
different European centres, a bias due to inclusion of
patients from only one center has been avoided.
Nevertheless, larger studies would be helpful to conﬁrm
the results of this observational study.
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